) -- Adam Feuerstein's take on the biotech week that was Nov. 19, 2010:
The week's best-performing stocks in the sector:
China Shenghuo Pharmaceutical Holdings
( KUN) (+26%)
FDA advisory panel votes 13-2 to recommend the approval of
Human Genome Sciences'
( HGSI) lupus drug Benlysta. Read the
rumored to be eyeing a competing takeover offer for
says still on track to sign a major RNAi drug partnership before the end of the year.
> > Bull or Bear? Vote in Our Poll
said to be
in wake of insider -trading allegations. (via New York Times)
The week's worst-performing stocks:
Medicare panel endorses on-label use of
prostate cancer therapy Provenge.
rumored to be considering acquisition of Swiss biotech firm Actelion.
cuts 4,800 jobs in a corporate restructuring
axes the company's research efforts into RNAi drug
development. (via Pharmalot, In the Pipeline)
European regulators accept approval application for
lymphoma drug Pixuvri.
: Interim phase II ovarian and prostate cancer data for XL184.
FDA advisory panel votes 8-7 with one abstention to recommend approval of
MELAFind skin cancer detection device. Read the
presents interim phase II data on limb ischemia drug.
presents phase II data on cholesterol drug.
Xgeva for prevention of bone fractures in cancer patients.
( SOMX) prices 8.8 million shares at $2.95 a share.
halt study of experimental blood thinner apixaban due to an increase in bleeding.
Results from late-stage study show
. (via Bloomberg)
(via WSJ Health Blog)
(via InVivo Blog)
sells 20 million shares at $4.40 a share.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.